434-07-1

• 常用中文名：康复龙
• 常用英文名：Oxymetholone
• CAS号：434-07-1
• 分子式：C₂₁H₃₂O₃
• 分子量：332.477
• 相关类别： 原料药 激素及调节内分泌功能类药 雄激素及同化激素类药
• 发布时间：2018-07-08 16:42:35
• 更新时间：2026-06-30 18:55:31

• 康力龙的中间体。本身为蛋白同化激素类药物，能促进蛋白质合成和抑制蛋白质异生，并能降低血胆固醇、减少钙磷排泄和减轻骨髓抑制，促进发育，促进组织新生和肉芽形成。对肾上腺皮质激素长期使用引起的肾上腺皮质功能减退有预防及对抗作用。

名称

• 中文名: 羟甲烯龙
• 英文名: oxymetholone
• 中文别名: 羟甲烯龙(康复龙); 康复龙(甾体); 康复龙,17Β-羟基-2-羟亚甲基-17Α-甲基-5Α-雄甾(烷)-3-酮; 康力龙杂质B; 2-羟亚甲基-17α-甲基-5α-雄甾(烷)-17β-醇-3-酮; 羟甲稀龙; 羟次甲氢龙; 羟甲睾丸素; 17β-羟基-2-羟亚甲基-17α-甲基-5α-雄甾(烷)-3-酮; 康复龙(羟甲烯龙); 枸橼酸托法替尼; 羟甲烯龙 标准品; 康复路; 康力龙杂质B 标准品; 司坦唑醇杂质B
• 英文别名: 17-beta-hydroxy-2-(hydroxymethylene)-17-methyl-5-alpha-androstan-3-on; Oximetolona; Pavisoid; 17-hydroxy-2-(hydroxymethylene)-17-methyl-,(alpha,17beta)-androstan-3-on; MFCD00869395; 5ALPHA-ANDROSTAN-17ALPHA-METHYL-17BETA-OL-2-HYDROXYMETHYLENE-3-ONE; Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5alpha,17beta); Anasteronal; Protanabol; 17-alpha-Methyl-2-hydroxymethylene-17-hydroxy-5-alpha-androstan-3-one; Stanozolol impurity B; 5-alpha-Androstan-3-one, 17-beta-hydroxy-2-(hydroxymethylene)-17-methyl; OxyMetholone (Anadrol); Zenalosyn; 17BETA-HYDROXY-2-(HYDROXYMETHYLENE)-17-METHYL-5ALPHA-ANDROSTAN-3-ONE; ANASTERONE; Raboral; (2Z,8R,9S,10S,13S,14S,17R)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one; oxymethalone; 2-Hydroxymethylene-17a-methylandrostan-17b-ol-3-one; Pdroyd; Oxymetholon Anadrol; 4,5-Dihydro-2-hydroxymethylene-17-alpha-methyltestosterone; 17beta-hydroxy-2-(hydroxymethylene)-17-methyl-5alpha-androstan-3-on; oximetholonium; oxymetholone-deascheduleiii; Anadrol; Roboral; Adroidin; 17-beta-androstan-3-one,17-hydroxy-2-(hydroxymethylene)-17-methyl-5-alph; 17-beta-Hydroxy-2-hydroxymethylene-17-alpha-methyl-3-androstanone; (5α,17β)-17-Hydroxy-2-(hydroxyMethylene)-17-Methylandrostan-3-one; ci406; 17beta-Hydroxy-2-(hydroxymethylene)-17-methyl-5alpha-androstan-3-one Anasterone; CI-406; (2Z,5S,8R,9S,10S,13S,14S,17S)-17-Hydroxy-2-(hydroxymethylene)-10,13,17-trimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one; (2Z,5α,17β)-17-hydroxy-2-(hydroxymethylidene)-17-methylandrostan-3-one; Anapolon; (2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxyméthylidène)-10,13,17-triméthylhexadécahydro-3H-cyclopenta[a]phénanthrén-3-one; Oximetholonum; Oxymethenolone; Anasteron; 17-Hydroxy-2-(hydroxymethylene)-17-methyl-5-alpha-17-beta-androst-3-one; 4,5alpha-dihydro-2-hydroxymethylene-17alpha-methyltestosterone; androstan-3-one,17-hydroxy-2-(hydroxymethylene)-17-methyl-,(5-alpha,17-beta; 5-alpha,17-beta-Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl; 17b-hydroxy-2-hydroxymethylene-17a-methyl-3-androstanone; Synasteron; 17-Hydroxy-2-hydroxymethylene-17-methyl-5-androstan-3-one; (2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one; (2Z,5α,17β)-17-Hydroxy-2-(hydroxymethylene)-17-methylandrostan-3-one; 17-beta-Hydroxy-2-(hydroxymethylene)-17-alpha-methyl-5-alpha-androstan-3-one; 2-Hydroxymethylene-17a-methyl-17b-hydroxy-5a-androstan-3-one; 4,5a-Dihydro-2-hydroxymethylene-17a-methyltestosterone; EINECS 207-098-6; 4,5-dihydro-2-hydroxymethylene-17-a-methyltestosterone; Oximetholone; Oxitosona-50; (2Z,5α,17β)-17-Hydroxy-2-(hydroxymethyliden)-17-methylandrostan-3-on; Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β); 17-Hydroxy-2-(hydroxymethylene)-17-methylandrostan-3-one; Adroyd; Anadroyd; OxyMetholon; 17-hydroxy-5-alpha-androstan-3-one; 5-ALPHA-ANDROSTAN-2-HYDROXYMETHYLENE-17-ALPHA-METHYL-17-BETA-OL-3-ONE; Becorel; (5a,17b)-17-Hydroxy-2-(hydroxymethylene)-17-methylandrostan-3-one; anapalon; 3-c)(1,2,5)oxadiazol-17-ol,17-methyl-,(5-alpha,17-beta)-androstano(; Androstano(2,3-c)(1,2,5)oxadiazol-17-ol, 17-methyl-, (5-alpha,17-beta); Plenastril; (2Z,5S,8R,9S,10S,13S,14S,17S)-17-Hydroxy-2-(hydroxymethyliden)-10,13,17-trimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-on

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 465.9±45.0 °C at 760 mmHg
• 熔点: 172-180°C
• 分子式: C₂₁H₃₂O₃
• 分子量: 332.477
• 闪点: 249.7±25.2 °C
• 精确质量: 332.235138
• PSA: 57.53000
• LogP: 4.22
• 外观性状: 白色结晶粉末
• 蒸汽压: 0.0±2.6 mmHg at 25°C
• 折射率: 1.590
• 储存条件: 2~8°C
• 分子结构:

  1、 摩尔折射率：95.89

  2、 摩尔体积（m³/mol）：284.2

  3、 等张比容（90.2K）：757.0

  4、 表面张力（dyne/cm）：50.3

  5、 极化率（10 ^-24cm ³）：38.01

• 更多:

  一、物性数据

  性状：白色结晶性粉末，无嗅

  密度（g/mL,25/4℃）：不可用

  相对蒸汽密度（g/mL,空气=1）：不可用

  熔点（ºC）：173-176

  沸点（ºC,常压）：不可用

  沸点（ºC,5.2kPa）：不可用

  折射率：不可用

  闪点（ºC）：不可用

  比旋光度（º）：不可用

  自燃点或引燃温度（ºC）：不可用

  蒸气压（kPa,25ºC）：不可用

  饱和蒸气压（kPa,60ºC）：不可用

  燃烧热（KJ/mol）：不可用

  临界温度（ºC）：不可用

  临界压力（KPa）：不可用

  油水（辛醇/水）分配系数的对数值：不可用

  爆炸上限（%,V/V）：不可用

  爆炸下限（%,V/V）：不可用

  溶解性：不溶于水，易溶于氯仿，溶于二氧六环、植物油，略溶于乙醇、乙醚

毒性和生态

毒理学数据: 二、毒理学数据： 急性毒性：不可用。 生态学数据: 三、生态学数据： 1、其它有害作用：该物质对环境可能有危害，对水体应给予特别注意。 CHEMICAL IDENTIFICATION RTECS NUMBER : BV8060000 CHEMICAL NAME : 5-alpha,17-beta-Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl- CAS REGISTRY NUMBER : 434-07-1 LAST UPDATED : 199712 DATA ITEMS CITED : 19 MOLECULAR FORMULA : C21-H32-O3 MOLECULAR WEIGHT : 332.53 WISWESSER LINE NOTATION : L E5 B666 OVTJ A1 E1 FQ F1 P1Q HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human DOSE/DURATION : 46 mg/kg/14W-I TOXIC EFFECTS : Liver - liver function tests impaired TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >1 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 5200 mg/kg/13W-I TOXIC EFFECTS : Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood - changes in other cell count (unspecified) Blood - changes in erythrocyte (RBC) count TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - child DOSE/DURATION : 270 mg/kg/9W-C TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Liver - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 2336 mg/kg/2Y-C TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Liver - jaundice (or hyperbilirubinemia) hepatocellular Liver - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Human - child DOSE/DURATION : 3050 mg/kg/3Y-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Liver - tumors TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - child DOSE/DURATION : 3735 mg/kg/3Y-C TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Liver - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 20 mg/kg SEX/DURATION : female 17-20 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 128 mg/kg SEX/DURATION : male 10 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 150 mg/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 28 mg/kg SEX/DURATION : female 14 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 14 mg/kg SEX/DURATION : female 14 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 30 mg/kg SEX/DURATION : female 1-3 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) MUTATION DATA TYPE OF TEST : Micronucleus test TEST SYSTEM : Rodent - hamster Embryo DOSE/DURATION : 10 mg/L REFERENCE : MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 392,61,1997 *** REVIEWS *** IARC Cancer Review:Animal No Adequate Data IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,96,1987 TOXICOLOGY REVIEW BIREBV Biology of Reproduction. (Soc. for the Study of Reproduction, 309 W. Clark St., Champaign, IL 61820) V.1- 1969- Volume(issue)/page/year: 8,259,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X6172 No. of Facilities: 28 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 742 (estimated) No. of Female Employees: 359 (estimated)

安全

• 符号: GHS08
• 信号词: Warning
• 危害声明: H351-H361
• 警示性声明: P281
• 个人防护装备: Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
• 危害码 (欧洲): T: Toxic;
• 风险声明 (欧洲): R40
• 安全声明 (欧洲): S53-S22-S26-S36/37/39
• 危险品运输编码: NONH for all modes of transport
• WGK德国: 3
• RTECS号: BV8060000
• 海关编码: 2937290023

上下游产品

上游产品  0
下游产品  2
360-66-7 6251-57-6

制备

可用番麻皂素或剑麻皂素经乙酰化、还原、开环、氧化、水解、消除、肟化、重排、水解、加成、氧化、水解、缩合等多步反应制得该品。

海关

海关编码	2937290023